For UK pharmaceutical and life sciences leaders
Your drug could be launch-ready before NICE will let the NHS buy it
A NICE technology appraisal can take many months after submission. Without a submission strategy built alongside your commercial plan, that gap becomes a period of zero NHS revenue you cannot recover.
Two minutes. Solva follows up with specific market access and bridging options.
- Product launch delays despite marketing authorisation
- NHS prescribers hesitant to adopt new treatments without NICE guidance
- Missed opportunities for patient access and revenue generation
- Increased pressure from investors and stakeholders due to slow market uptake
- Inefficient resource allocation within pharmaceutical companies due to uncertainty in market access timelines
- Increased administrative burden and rework for regulatory and market access teams
- Significant foregone NHS revenue for pharmaceutical companies due to delayed market access
- Increased R&D costs without corresponding revenue generation, impacting investment in future innovations
- Delayed patient access to innovative treatments, potentially worsening health outcomes for conditions where early intervention is critical
- Increased burden on NHS resources due to prolonged use of less effective or older treatments
- Damage to pharmaceutical company's reputation as an innovator and partner to the NHS
- Erosion of trust with patient advocacy groups and healthcare professionals due to perceived delays in treatment availability
Products benefiting from NICE Advice's scientific advice service had a shorter time from marketing authorisation to the publication of NICE guidance, with a median of 312 days compared to 400 days for those without, a difference of nearly 3 months (NICE, 2024)
Frequently asked questions
Why does this problem persist?
NICE technology appraisals and health technology assessments are the primary gateway to NHS formulary inclusion in England. Companies that don't plan their NICE submission strategy in parallel with clinical development often find themselves in a commercial limbo - product licensed but not yet recommended, with NHS prescribers unwilling to use it without NICE guidance.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.